A Randomized, Double-blind, Active-controlled Clinical Study Evaluating the Immunogenicity and Safety of Omicron BA.4/5-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People Aged 18 Years and Older With Different Immunization Programs
Latest Information Update: 08 Sep 2023
At a glance
- Drugs ZF 2001 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
Most Recent Events
- 08 Sep 2023 New trial record